Ng recombinant vaccinia: implications for vaccine improvement. J Exp Med. 1992; 176:169?76. [PubMed: 1377222] 10.

Ng recombinant vaccinia: implications for vaccine improvement. J Exp Med. 1992; 176:169?76. [PubMed: 1377222] 10. Burrows SR, Sculley TB, Misko IS, Schmidt C, Moss DJ. An Epstein-Barr virus- certain cytotoxic T cell epitope in EBV nuclear antigen 3 (EBNA three). J Exp Med. 1990; 171:345?49. [PubMed: 1688611] 11? Elliott SL, Suhrbier A, Miles JJ, Lawrence G, Pye SJ, Le TT, Rosenstengel A, Nguyen T, Allworth A, Burrows SR, et al. Phase I trial of a CD8+ PRMT4 Species T-cell peptide epitope-based vaccine for infectious mononucleosis. J Virol. 2008; 82:1448?457. A feasibility trial that demonstrated Amylases site security and immunogenicity of an EBV CD8+ T-cell peptide vaccine. Though not practical for common use due to HLA restriction, it may be studied in subjects whose HLA is effectively characterized, like pretransplant candidates. [PubMed: 18032491] 12 . Hui EP, Taylor GS, Jia H, Ma BB, Chan SL, Ho R, Wong WL, Wilson S, Johnson BF, Edwards C, et al. Phase I trial of recombinant modified vaccinia Ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma individuals. Cancer Res. 2013; 73:1676?688. A completely developed trial whose hypothesis is the fact that enhanced recognition of tumor cells by means of their expression of EBNA antigens EBNA-1 and LMP-2 will likely be therapeutic. Security, immunogenicity, and a dose-response effect were demonstrated. [PubMed: 23348421] 13. Balfour HH Jr. Epstein-Barr virus vaccine for the prevention of infectious mononucleosis–and what else? J Infect Dis. 2007; 196:1724?726. [PubMed: 18190249]NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author ManuscriptCurr Opin Virol. Author manuscript; accessible in PMC 2015 June 01.BalfourPage14. Nemerow GR, Mold C, Schwend VK, Tollefson V, Cooper NR. Identification of gp350 because the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) for the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d. J Virol. 1987; 61:1416?1420. [PubMed: 3033269] 15. Moss DJ, Pope JH. Assay of your infectivity of Epstein-Barr virus by transformation of human leucocytes in vitro. J Gen Virol. 1972; 17:233?36. [PubMed: 4344316] 16. Sashihara J, Burbelo PD, Savoldo B, Pierson TC, Cohen JI. Human antibody titers to Epstein-Barr Virus (EBV) gp350 correlate with neutralization of infectivity greater than antibody titers to EBV gp42 working with a speedy flow cytometry-based EBV neutralization assay. Virology. 2009; 391:249?56. [PubMed: 19584018] 17. Moghaddam A, Rosenzweig M, Lee-Parritz D, Annis B, Johnson RP, Wang F. An animal model for acute and persistent Epstein-Barr virus infection. Science. 1997; 276:2030?033. [PubMed: 9197263] 18? Sashihara J, Hoshino Y, Bowman JJ, Krogmann T, Burbelo PD, Coffield VM, Kamrud K, Cohen JI. Soluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that become infected with virus after challenge. PLoS Pathog. 2011; 7:e1002308. An important study in which rhesus macques were protected from an EBV challenge infection right after getting gp350 vaccine. [PubMed: 22028652] 19? Balfour HH Jr, Odumade OA, Schmeling DO, Mullan BD, Ed JA, Knight JA, Vezina HE, Thomas W, Hogquist KA. Behavioral, virologic, and immunologic variables related with acquisition and severity of key Epstein-Barr virus infection in university students. J Infect Dis. 2013; 207:80?8. A prospective study demonstrating the important disease burden of main EBV infection in EBV-na e college freshmen. Such students are best subjects.